Publication:
P465L-PPAR gamma mutation confers partial resistance to the hypolipidaemic action of fibrates

dc.contributor.authorRodriguez-Cuenca, Sergio
dc.contributor.authorCarobbio, Stefania
dc.contributor.authorBarcelo-Coblijn, Gwendolyn
dc.contributor.authorPrieur, Xavier
dc.contributor.authorRelat, Joana
dc.contributor.authorAmat, Ramon
dc.contributor.authorCampbell, Mark
dc.contributor.authorDias, Ana Rita
dc.contributor.authorBahri, Myriam
dc.contributor.authorGray, Sarah L
dc.contributor.authorVidal-Puig, Antonio
dc.date.accessioned2024-09-06T09:56:41Z
dc.date.available2024-09-06T09:56:41Z
dc.date.issued2018-10
dc.description.abstractAims: Familial partial lipodystrophic syndrome 3 (FPLD3) is associated with mutations in the transcription factor PPAR gamma. One of these mutations, the P467L, confers a dominant negative effect. We and others have previously investigated the pathophysiology associated with this mutation using a humanized mouse model that recapitulates most of the clinical symptoms observed in patients who have been phenotyped under different experimental conditions. One of the key clinical manifestations observed, both in humans and mouse models, is the ectopic accumulation of fat in the liver. With this study we aim to dissect the molecular mechanisms that contribute to the excessive accumulation of lipids in the liver and characterize the negative effect of this PPAR gamma mutation on the activity of PPAR alpha in vivo when activated by fibrates. Material and Methods: P465L-PPAR mutant and wild-type mice were divided into 8 experimental groups, 4 different conditions per genotype. Briefly, mice were fed a chow diet or a high-fat diet (HFD 45% Kcal from fat) for a period of 28 days and treated with WY14643 or vehicle for five days before culling. At the end of the experiment, tissues and plasma were collected. We performed extensive gene expression, fatty acid composition and histological analysis in the livers. The serum collected was used to measure several metabolites and to perform basic lipoprotein profile. Results: P465L mice showed increased levels of insulin and free fatty acids (FFA) as well as increased liver steatosis. They also exhibit decreased levels of very low density lipoproteins (VLDL) when fed an HFD. We also provide evidence of impaired expression of a number of well-established PPAR alpha target genes in the P465L mutant livers. Conclusion: Our data demonstrate that P465L confers partial resistance to the hypolipidemic action of fibrates. These results show that the fatty liver phenotype observed in P465L mutant mice is not only the consequence of dysfunctional adipose tissue, but also involves defective liver metabolism. All in all, the deleterious effects of P465L-PPAR gamma mutation may be magnified by their collateral negative effect on PPAR alpha function.en
dc.description.sponsorshipThis work was funded by Wellcome Trust, MRC MDU (MC_UU_12012/2), FP7-MITIN (Integration of the System Models of Mitochondrial Function and Insulin Signalling and its Application in the Study of Complex Diseases) (Grant Agreement 223450) and H2020 EPoS (Elucidating Pathways of Steatohepatitis) (Grant Agreement 634413). Disease Model Core, Biochemistry Assay Lab and the Histology Core are funded by MRC_MC_UU_12012/5 and a Wellcome Trust Strategic Award [100574/Z/12/Z].es_ES
dc.format.number10es_ES
dc.format.page2339-2350es_ES
dc.format.volume20es_ES
dc.identifier.citationRodriguez-Cuenca S, Carobbio S, Barceló-Coblijn G, Prieur X, Relat J, Amat R, et al. P465L-PPAR gamma mutation confers partial resistance to the hypolipidaemic action of fibrates. Diabetes Obes Metab. 2018 Oct;20(10):2339-50. Epub 2018 Jun 27.en
dc.identifier.doi10.1111/dom.13370
dc.identifier.e-issn1463-1326es_ES
dc.identifier.issn1462-8902
dc.identifier.journalDiabetes Obesity & Metabolismes_ES
dc.identifier.otherhttp://hdl.handle.net/20.500.13003/9094
dc.identifier.pubmedID29790245es_ES
dc.identifier.puiL623854757
dc.identifier.scopus2-s2.0-85051946983
dc.identifier.urihttps://hdl.handle.net/20.500.12105/22618
dc.identifier.wos444185800003
dc.language.isoengen
dc.publisherWiley
dc.relation.publisherversionhttps://dx.doi.org/10.1111/dom.13370en
dc.rights.accessRightsopen accessen
dc.rights.licenseAttribution 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectfatty liver
dc.subjectfibrates
dc.subjectlipodystrophy
dc.subjectP465L-PPAR gamma
dc.subjectPPAR alpha
dc.subject.decsSustitución de Aminoácidos*
dc.subject.decsProlina*
dc.subject.decsAnimales*
dc.subject.decsMutación Missense*
dc.subject.decsResistencia a Medicamentos*
dc.subject.decsPPAR gamma*
dc.subject.decsModelos Animales de Enfermedad*
dc.subject.decsHígado Graso*
dc.subject.decsÁcidos Fíbricos*
dc.subject.decsLeucina*
dc.subject.decsHipolipemiantes*
dc.subject.decsRatones Transgénicos*
dc.subject.decsHiperlipidemias*
dc.subject.decsRatones*
dc.subject.meshHyperlipidemias*
dc.subject.meshPPAR gamma*
dc.subject.meshMice, Transgenic*
dc.subject.meshHypolipidemic Agents*
dc.subject.meshLeucine*
dc.subject.meshMutation, Missense*
dc.subject.meshFatty Liver*
dc.subject.meshDisease Models, Animal*
dc.subject.meshDrug Resistance*
dc.subject.meshAnimals*
dc.subject.meshAmino Acid Substitution*
dc.subject.meshProline*
dc.subject.meshFibric Acids*
dc.subject.meshMice*
dc.titleP465L-PPAR gamma mutation confers partial resistance to the hypolipidaemic action of fibratesen
dc.typeresearch articleen
dspace.entity.typePublication
relation.isPublisherOfPublicationd81e762a-95f7-4917-88a1-8004b3b8caa7
relation.isPublisherOfPublication.latestForDiscoveryd81e762a-95f7-4917-88a1-8004b3b8caa7

Files